ManziSSánchez-GuerreroJMerrillJT. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis2012; 71: 1833–1838.
2.
YeYQianJGuYChenXYeS. Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol2011; 30: 981–986.
3.
NarváezJRíos-RodriguezVde la FuenteD. Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence. Semin Arthritis Rheum2011; 41: 364–372.
4.
VitalEMDassSBuchMH. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum2011; 63: 3038–3047.
5.
PintoLFVelásquezCJPrietoCMestraLForeroEMárquezJD. Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus2011; 20: 1219–1226.
6.
Fernández-NebroAde la FuenteJLCarreñoL. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus2012; 21: 1063–1076.
7.
IaccarinoLBartoloniECarliL. Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian Multicentre Registry. Clin Exp Rheumatol2015; 33: 449–456.
8.
HickmanRAHira-KazalRYeeCSToescuVGordonC. The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol2015; 34: 263–271.
9.
Braun-MoscoviciYButbul-AvielYGuralnikL. Rituximab: Rescue therapy in life-threatening complications or refractory autoimmune diseases: A single center experience. Rheumatol Int2013; 33: 1495–1504.
10.
SanzPGGarcía MéndezCVCuetoAL. Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus and good outcome with rituximab treatment. Rheumatol Int2012; 32: 4061–4063.
